Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Effect of Statins on the No-Reflow Phenomenon

The Effect of Statins on the No-Reflow Phenomenon Am J Cardiovasc Drugs 2009; 9 (2): 81-89 ORIGINAL RESEARCH ARTICLE 1175-3277/09/0002-0081/$49.95/0 ª 2009 Adis Data Information BV. All rights reserved. The Effect of Statins on the No-Reflow Phenomenon An Observational Study in Patients with Hyperglycemia before Primary Angioplasty Jing-Lin Zhao, Yue-Jin Yang, Wei-Dong Pei, Yu-Hua Sun and Ji-Lin Chen Department of Cardiology, Cardiovascular Institute and Fu-Wai Heart Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Abstract Background: An association between admission plasma glucose levels and an increased risk of no-reflow has been well documented. Although HMG-CoA reductase inhibitor (statin) therapy can reduce no-reflow, little is known about its effect on no-reflow in patients with hyperglycemia. In the present study, we investigated whether pretreatment with a statin could reduce no-reflow in patients with hyperglycemia, who underwent primary coronary intervention for acute myocardial infarction (AMI). Methods: A total of 259 consecutive patients who underwent primary angioplasty for a first AMI were studied. Blood glucose and creatinine kinase levels were measured on admission. All patients underwent 2-dimensional echocardiography and electrocardiographic analysis just after admission. No-reflow was defined as a Thrombolysis in Myocardial Infarction (TIMI) flow grade <3. Hyperglycemia was defined as a blood glucose level ‡10 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

The Effect of Statins on the No-Reflow Phenomenon

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/the-effect-of-statins-on-the-no-reflow-phenomenon-T9p25nf9HI

References (24)

Publisher
Springer Journals
Copyright
Copyright © 2009 by Adis Data Information BV
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/BF03256579
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs 2009; 9 (2): 81-89 ORIGINAL RESEARCH ARTICLE 1175-3277/09/0002-0081/$49.95/0 ª 2009 Adis Data Information BV. All rights reserved. The Effect of Statins on the No-Reflow Phenomenon An Observational Study in Patients with Hyperglycemia before Primary Angioplasty Jing-Lin Zhao, Yue-Jin Yang, Wei-Dong Pei, Yu-Hua Sun and Ji-Lin Chen Department of Cardiology, Cardiovascular Institute and Fu-Wai Heart Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China Abstract Background: An association between admission plasma glucose levels and an increased risk of no-reflow has been well documented. Although HMG-CoA reductase inhibitor (statin) therapy can reduce no-reflow, little is known about its effect on no-reflow in patients with hyperglycemia. In the present study, we investigated whether pretreatment with a statin could reduce no-reflow in patients with hyperglycemia, who underwent primary coronary intervention for acute myocardial infarction (AMI). Methods: A total of 259 consecutive patients who underwent primary angioplasty for a first AMI were studied. Blood glucose and creatinine kinase levels were measured on admission. All patients underwent 2-dimensional echocardiography and electrocardiographic analysis just after admission. No-reflow was defined as a Thrombolysis in Myocardial Infarction (TIMI) flow grade <3. Hyperglycemia was defined as a blood glucose level ‡10

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Aug 17, 2012

There are no references for this article.